|
FY2025
12 months to Dec 28, 2025
|
FY2024
12 months to Dec 29, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Jan 1, 2023
|
FY2021
12 months to Jan 2, 2022
|
|
|---|---|---|---|---|---|
| Cash flows used in operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities | |||||
| Depreciation, accretion and amortization | |||||
| Stock-based compensation | |||||
| Change in fair value of common stock warrants | |||||
| Impairment of equipment | |||||
| Gain on bargain purchase of assets | |||||
| Impairment and loss on disposal of long-lived assets | |||||
| Interest expense (non-cash) | |||||
| Others | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts and notes receivables | |||||
| Inventory | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Accrued expenses and compensation | |||||
| Deferred revenue | |||||
| Deferred tax liability | |||||
| Other liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchase of property and equipment | |||||
| Payment for business acquisition | |||||
| Routejade acquisition, net of cash and restricted cash acquired | |||||
| Purchases of investments | |||||
| Maturities of investments | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from Business Combination and PIPE financing | |||||
| Payments of transaction costs related to common stock issuance | |||||
| Proceeds from issuance of common stock, net of issuance costs | |||||
| Payments of issuance costs related to common stock and warrant dividends | |||||
| Proceeds from issuance of convertible senior notes and loan borrowing | |||||
| Payments of debt issuance costs | |||||
| Repayment of debt | |||||
| Proceeds from issuance of common stock under employee stock purchase plan | |||||
| Payroll tax payments for shares withheld upon vesting of RSUs | |||||
| Proceeds from the exercise of stock options and issuance of common stock under ATM, net of issuance costs | |||||
| Repurchase of unvested restricted common stock | |||||
| Repurchase of common stock | |||||
| Net cash provided by financing activities | |||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | |||||
| Change in cash, cash equivalents, and restricted cash | |||||
| Cash and cash equivalents and restricted cash, beginning of period | |||||
| Cash and cash equivalents and restricted cash, end of period | |||||
| Supplemental cash flow disclosure: | |||||
| Cash paid for interest | |||||
| Net liabilities assumed from Business Combination | |||||
| Cash paid for income taxes | |||||
| Purchase of property and equipment included in liabilities | |||||
| Cashless warrant exercise | |||||
| Accrued issuance costs | |||||
Loading...